-
Mashup Score: 2The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra - 2 year(s) ago
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra - 2 year(s) ago
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The performance of a genomic classifier score in the phase 3 SAKK 09/10 trial in patients with biochemical progression. @a_dalpra @SylvesterCancer joins @CaPsurvivorship @DanaFarber on UroToday > https://t.co/3CopRVT816 @Decipher_VCYT @Veracyte @ASTRO_org #ASTRO21 @SAKK_ch https://t.co/zTXTdFmDSO
-
-
Mashup Score: 1The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra - 2 year(s) ago
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The performance of a genomic classifier score in the phase 3 SAKK 09/10 trial in patients with biochemical progression. @a_dalpra @SylvesterCancer joins @CaPsurvivorship @DanaFarber on UroToday > https://t.co/3CopRVT816 @Decipher_VCYT @Veracyte @ASTRO_org #ASTRO21 @SAKK_ch https://t.co/tkxxHrzSck
-
-
Mashup Score: 1The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra - 2 year(s) ago
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The performance of a genomic classifier score in the phase 3 SAKK 09/10 trial in patients with biochemical progression. @a_dalpra @SylvesterCancer joins @CaPsurvivorship @DanaFarber on UroToday > https://t.co/3CopRVT816 @Decipher_VCYT @Veracyte @ASTRO_org #ASTRO21 @SAKK_ch https://t.co/xdpAQEMWSd
-
-
Mashup Score: 1
ASTRO 2021 biomarkers and salvage radiotherapy prostate cancer, the performance of a genomic classifier within a phase 3 randomized trial of dose escalated salvage radiotherapy after radical prostatectomy, Genomic classifiers prostate cancer, the role of the genomic classifier in patients treated within The SAKK 09/10 trial (NCT01272050)
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Performance of a genomic classifier within a phase 3 randomized trial of dose-escalated salvage radiotherapy after radical prostatectomy. @a_dalpra @SylvesterCancer. #ASTRO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/Yt6LkltDBZ @ASTRO_org https://t.co/fURRWLk5wi
-
-
Mashup Score: 0ASTRO 2021: Prostate Cancer: Better Living Through Biomarkers - 2 year(s) ago
ASTRO 2021 biomarkers and salvage radiotherapy prostate cancer, the SAKK 09/10 trial, a phase I trial of neoadjuvant stereotactic body radiotherapy, biomarker studies in high-risk intact disease include the genomic classifier analysis from three high-risk RTOG trials, and a PSMA PET-derived risk stratification tool.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
#ProstateCancer: Better living through biomarkers. Presentation by @BrianBaumannMD @WUSTL. #ASTRO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/KqmMzgo1Bo @ASTRO_org https://t.co/YGPP5K4Mg2
-
-
Mashup Score: 0
ASTRO 2021 biomarkers and salvage radiotherapy prostate cancer, the validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202 9413 and 9902 phase III randomized trials, decipher genomic classifier prostate cancer, decipher prostate cancer test
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials: A biopsy-based individual patient meta-analysis in high-risk #ProstateCancer. @DrPaulNguyen @DanaFarber #ASTRO21 > https://t.co/SxY8XCcDb8 @zklaassen_md https://t.co/ihirHprxDT
-
-
Mashup Score: 4Become an Advocate - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO) - 2 year(s) ago
ASTRO has a new Advocacy Action Center! Check out our newest resource for making your voice heard in Washington. Send emails and tweet directly to your Senators and Representatives to make sure they act on the issues important to the radiation oncology community.
Source: ASTROCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent study from #ASTRO21 found prior authorization delays for radiation therapy treatments create a financial impact of over $40 mil. annually for academic medical centers. Visit https://t.co/Tk6ZOqbJor & ask Congress to #FixPriorAuth https://t.co/tTEuwN3YtR
-
-
Mashup Score: 1
ASTRO 2021 biomarkers and salvage radiotherapy prostate cancer, the validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202 9413 and 9902 phase III randomized trials, decipher genomic classifier prostate cancer, decipher prostate cancer test
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials: A biopsy-based individual patient meta-analysis in high-risk #ProstateCancer. @DrPaulNguyen @DanaFarber #ASTRO21 > https://t.co/SxY8XCcDb8 @zklaassen_md https://t.co/a2Fe3CkLT8
-
-
Mashup Score: 2
ASTRO 2021 biomarkers and salvage radiotherapy prostate cancer, the performance of a genomic classifier within a phase 3 randomized trial of dose escalated salvage radiotherapy after radical prostatectomy, Genomic classifiers prostate cancer, the role of the genomic classifier in patients treated within The SAKK 09/10 trial (NCT01272050)
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Performance of a genomic classifier within a phase 3 randomized trial of dose-escalated salvage radiotherapy after radical prostatectomy. @a_dalpra @SylvesterCancer. #ASTRO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/Yt6LkltDBZ @ASTRO_org https://t.co/rSJZJio4gs
-
The performance of a genomic classifier score in the phase 3 SAKK 09/10 trial in patients with biochemical progression. @a_dalpra @SylvesterCancer joins @CaPsurvivorship @DanaFarber on UroToday > https://t.co/3CopRVT816 @Decipher_VCYT @Veracyte @ASTRO_org #ASTRO21 @SAKK_ch https://t.co/VZalxrhVu0